Liraglutide

Overview

Liraglutide is a 31-amino-acid GLP-1 receptor agonist and the molecule that first established the fatty-acid-lipidation half-life strategy later carried through to Semaglutide and Tirzepatide. The structure pairs a C16 palmitoyl moiety, attached through a γ-glutamyl spacer at Lys26, with an Arg34-for-Lys34 substitution that blocks off-target acylation during synthesis; the C16 chain is the shorter end of the lipidation series the GLP-1 class is built on, which is why Liraglutide is a frequent comparator in incretin structure-activity studies. It is the active ingredient of approved finished drugs under separate brand names, but the material supplied here is a reference reagent only — characterized as a standard, not described for any therapeutic outcome. Lyochem characterizes each Liraglutide lot as an analytical reference standard. Every vial carries its own data packet: RP-HPLC purity (gradient method, UV 214 nm), ESI-MS identity within 0.5 Da of the theoretical 3751.20 g/mol, sequence confirmation by LC-MS/MS, counter-ion content, and water content by Karl Fischer. Because the 31-residue lipidated backbone sits at the more demanding end of routine SPPS, deletion sequences elute close to the target peak on RP-HPLC, so tandem-MS sequence verification is an available sequence-level add-on. Bacterial endotoxin (LAL) is an on-request add-on for in vivo metabolic-model work. Fills run mg-scale for reproducible aliquoting across a study series; this is reference-grade research material, distinct from compounding-scale API supply.

Applications & buyer fit

Specifications

CAS

204656-20-2

Molecular Formula

C172H265N43O51

Molecular Weight

3751.20 g/mol

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 30 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 13 hours

MOQ

On request

Lead time

10–18 days

Storage

-20°C, protect from light

Documentation available on request

• Lot-specific Certificate of Analysis (CoA)
• RP-HPLC chromatogram with peak integration
• ESI-MS identity confirmation (±0.5 Da)
• Sequence verification by LC-MS/MS
• Water content by Karl Fischer
• SDS / MSDS
• Counter-ion content (acetate / TFA)
• Peptide content (% net peptide)
• Bacterial endotoxin (LAL) on request — in vivo workflows

Regulatory note

Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form and not labelled for human administration. Liraglutide is the active ingredient of approved finished drugs under separate brand names, but the bulk active supplied here is a research reagent; buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.

Selected literature

1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322.
2. Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
3. Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
4. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155.
5. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med. 2005;22(8):1016-1023.
6. Joshi S, Das AK, Khunti K, Khunti S, Choudhari SY. A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2026;19:Article 570273.

Frequently asked questions